AMP

Association for Molecular Pathology

Molecular Pathology Economics Summit

July 15, 2022

Washington, D.C.

THANK YOU TO OUR SPONSORS

Asuragen®

a bio-techne® brand

.

Genentech

A Member of the Roche Group

AMP 2022 Molecular Pathology Economics Summit

July 15, 2022 • Washington, D.C.

Agenda at a Glance

Friday, July 15, 2022 – The Conrad, Conservatory Ballroom, Washington, D.C.

7:30 am	**Registration and Breakfast** (*Conservatory Gallery*)
8:00 am	Welcome and Opening Remarks
8:30 am	Real World Perspectives from Key Stakeholders: How the pandemic affected molecular diagnostic testing, the laboratories that perform these tests, and patient access
9:15 am	Real World Perspectives from Key Stakeholders: How CODING is a barrier for patient access
10:00 am	**Coffee Break** (*Conservatory Gallery*)
10:30 am	Real World Perspectives from Key Stakeholders: How PRICING is a barrier for patient access
11:15 am	Real World Perspectives from Key Stakeholders: How COVERAGE is a barrier for patient access
12:00 pm	**Lunch** (*Conservatory Gallery*)
12:30 pm	Introduction to Afternoon Sessions
12:45 pm	Innovation Lab – Part 1
2:00 pm	**Coffee Break and Vote Counting** (*Conservatory Gallery*)
2:30 pm	Innovation Lab – Part 2
3:00 pm	Closing Remarks and Next Steps
3:30 pm	**Departure**

Main Program

Friday, July 15, 2022

7:30 am — **Registration and Breakfast**

The Conrad Washington D.C., Conservatory Gallery, Level 2
950 New York Ave. NW
Washington, DC, 20001

8:00 am — **Welcome and Opening Remarks**

Conservatory Ballroom, Level 2

Speaker: **Samuel Caughron**, MD, Chair, AMP Economic Affairs Committee, *MAWD Pathology Group, P.A.*

8:30am-12:00pm — **Real World Perspectives from Key Stakeholders – *Session Overview***

Multiple stakeholders from different industries are affected by the economic challenges plaguing clinical molecular diagnostics. Each industry and stakeholder is uniquely impacted, but there is common alignment around an interest in improving the overall economics for diagnostic testing. Advances in diagnostic testing and closely related therapies are driving precision medicine, while at the same time continuing to challenge current paradigms for molecular diagnostic coding, coverage, and pricing. During the morning session, a series of roundtable discussions will be held, each focused on a specific topic: coding, pricing, and coverage as barriers for patient access as well as the impact of the pandemic on the field. At the table are a variety of industries and stakeholders, including clinical laboratories, pharmaceutical companies, in vitro diagnostic manufacturers, and patient advocacy groups, who will share their perspective on said topic(s). Interactive candid discussions will explore the unique challenges confronting each of these stakeholder groups, with the ultimate goal of mutual understanding and identification of common areas in which to assign resources to improve the economics in pursuit of best patient care.

Details regarding morning sessions on next page.

8:00 am	**Real World Perspectives from Key Stakeholders: How the pandemic affected molecular diagnostic testing, the laboratories that perform these tests, and patient access** Facilitator: **Amy Miller**, PhD The facilitator will lead a discussion with interested panel members representing a variety of stakeholder groups to unpack the themes revealed in the roundtable discussions.
9:15 am	**Real World Perspectives from Key Stakeholders: How CODING is a barrier for patient access** Facilitator: **Amy Miller**, PhD
10:00 am	**Coffee Break** *Conservatory Gallery, Level 2*
10:30 am	**Real World Perspectives from Key Stakeholders: How PRICING is a barrier for patient access** *Conservatory Ballroom, Level 2* Facilitator: **Amy Miller**, PhD The facilitator will lead a discussion with interested panel members representing a variety of stakeholder groups to unpack the themes revealed in the roundtable discussions
11:15 am	**Real World Perspectives from Key Stakeholders: How COVERAGE is a barrier for patient access** Facilitator: **Amy Miller**, PhD
12:00 pm	**Lunch** *Conservatory Gallery, Level 2*

12:30pm	**Introduction to Afternoon Sessions** *Conservatory Ballroom, Level 2* Speakers: **Samuel Caughron**, MD and **Amy Miller**, PhD
12:45 pm	**Innovation Lab – Part 1** Facilitator: **Amy Miller**, PhD In the first Innovation Lab session, selected participants will be given the floor to present and build support for their novel solutions that are designed to target and address overarching pain points identified by this community related to coding, coverage, and reimbursement of molecular diagnostic testing. This session provides a forum for ideas to be shared – with the goal of garnering broad perspectives on such an approach, as well as offer an opportunity to potentially garner support and resources to help accelerate these solutions. The audience will vote on the most promising idea and next steps.
2:00 pm	**Coffee Break** *Conservatory Gallery, Level 2*
2:30 pm	**Innovation Lab – Part 2** *Conservatory Ballroom, Level 2* Facilitator: **Amy Miller**, PhD The afternoon session will begin with attendees voting on the most promising Innovation Lab idea and the action items that they believe will have the most impact. Using the voting results, the facilitator will guide the attendees to help develop a cross-industry plan to support and push the winning idea forward within their respective stakeholder group over the next few years.
3:00 pm	**Closing Remarks and Next Steps** Speaker: **Samuel Caughron**, MD
3:30 pm	**Depart**

Biographies

Program Chair

Samuel K. Caughron, MD FCAP practices pathology in Kansas City where he is President & CEO and Director of the Molecular Lab at MAWD Pathology, as well as Chair of Pathology for AdventHealth Kansas City. He received his medical degree and AP/CP pathology training at Creighton University and completed a fellowship in Molecular Genetic Pathology at Vanderbilt.

Dr. Caughron has served on numerous local, regional, and national professional boards, committees, and advisory panels for pathologists within multiple organizations including the American Medical Association (AMA), College of American Pathologists (CAP), the American Pathology Foundation (APF) and the Association for Molecular Pathology (AMP). He is nationally recognized for his expertise in molecular coding, coverage, and pricing, and has served as Chair of AMP's Economic Affairs Committee since 2015. In that role, Dr. Caughron leads the organization's strategy and efforts around recognition and reimbursement for molecular services. In 2019 he conceived and served as Chair for the inaugural AMP Economic Summit.

Program Facilitator

Amy M. Miller, PhD, is President of the PhRMA Foundation, a leading independent nonprofit that funds foundational academic research advancing drug delivery, drug discovery, translational medicine, health equity, and value-driven health care. Dr. Miller leads strategic planning, fundraising, and the recruitment of pharmaceutical industry experts who comprise the award selection committees.

Dr. Miller has held nonprofit leadership roles for nearly 20 years. Before joining the PhRMA Foundation, she served as President and CEO of the Society for Women's Health Research (SWHR), a leading organization in promoting women's health. Prior to that, she was Executive Vice President of the Personalized Medicine Coalition (PMC), a 200+ member advocacy coalition focused on advancing the concept of personalized medicine across the health care ecosystem.

Before entering nonprofit management, Dr. Miller worked in government both within the National Institutes of Health and as an AAAS legislative fellow and policy adviser to Sen. Jay Rockefeller (D-WV), focused on welfare reform and domestic homeland security.

She holds a bachelor's degree from the University of New Orleans and a PhD from the University of Connecticut.

Planning Committee Members

Nicholas Bevins, MD PhD Dr. Bevins is currently the Laboratory Director of Sapient Bioanalytics – a biomarker discovery company. In this role, he oversees discovery and clinical implementation of sequencing and mass-spectrometry based biomarker testing. He is a member of the Association of Molecular Pathology, College of American Pathologists, and American Association of Clinical Chemistry. Dr. Bevins is board certified in clinical pathology. He completed his MD and residency training at the University of California, San Diego. He completed his PhD in cellular and molecular neuroscience at the Salk Institute.

Pranil Chandra, DO is a member of the American Society of Clinical Pathology, College of American Pathologists, and Association of Molecular Pathology (AMP). Dr. Chandra is currently the Vice-Chair of Coverage Decisions for the Economic Affairs Committee. In this role, Dr. Chandra provides leadership to AMP's response on any matters related to coverage of molecular pathology testing.

Dr. Chandra serves as Chief Medical Officer and Vice President of Genomic and Clinical Pathology Services at PathGroup, which is one of largest privately-owned pathology groups in the United States today. Dr. Chandra holds board certifications in anatomic and clinical pathology, hematopathology and molecular genetic pathology. He completed his AP/CP training and fellowships in hematopathology at NYU Langone Medical Center. This was followed by oncologic pathology and molecular pathology fellowships at the University of Texas-MD Anderson Cancer Center, where he served as Chief Fellow

Tanner Hagelstrom, PhD, MBA, FACMG is a dual certified in cytogenetics and molecular genetics. He currently serves as the senior laboratory director of oncology at Natera. Prior to Natera, he was the laboratory director of whole genome sequencing at Illumina, and assistant professor at the University of Nebraska Medical Center. He trained at the University of Colorado Anschutz Medical Campus and did all of his graduate work at Colorado State University. Tanner is an active member of the Association of Molecular Pathologist and serves on the Economic Affairs Committee.

(Continued on next page)

Jay Patel, MD, MBA is an associate professor of pathology at the University of Utah School of Medicine and Executive Director of Clinical Trials and PharmaDx at ARUP Laboratories. He is an active member of the Association for Molecular Pathology (AMP) where he serves as the vice chair for new codes and pricing on the Economic Affairs Committee. Dr. Patel is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty boards in hematology, and is a fellow of the College of American Pathologists. Dr. Patel's clinical interests include application of molecular diagnostics in the diagnosis and management of patients with hematologic malignancies and benign hematologic disorders.

Victoria M. Pratt, Ph.D., FACMG is theVice President at Molecular Diagnostics Quality Assessments, Optum Genomics. Dr. Pratt is a Medical and Clinical Molecular Geneticist board-certified by the American College of Medical Genetics. Prior to joining Optum Genomics, she was the Laboratory Director of the Pharmacogenomics and Molecular Genetics at Indiana University School of Medicine. She continues to be Adjunct Professor of Medical and Molecular Genetics at Indiana University.

Dr. Pratt is the Past President of Association for Molecular Pathology. Dr. Pratt continues to serve on the Centers for Disease Control and Prevention (CDC) GeT-RM program for reference materials for Molecular Genetics, the National Academy of Medicine's Roundtable on Genomics and Precision Health, and the American Medical Association's (AMA) Molecular Pathology Current Procedural Terminology (CPT) Advisory committee.

Dr. Pratt graduated with a Ph.D. in Medical and Molecular Genetics from Indiana University School of Medicine. Her fellowship training was in Ph.D. Medical and Clinical Molecular Genetics at Henry Ford Hospital, Detroit MI.

Salvatore Priore, MD, PhD, Dr. Salvatore Priore is an Assistant Professor of Clinical Pathology and Laboratory Medicine at the University of Pennsylvania, Perelman School of Medicine. He completed his residency in Anatomic Pathology and fellowship in Molecular Genetic Pathology at the University of Pennsylvania. He received his MD and PhD degrees from the University of Rochester as a member of the Medical Scientist Training Program. He completed a post-doctoral fellowship in the laboratory of Yi Xing in the Center for Computational and Genomic Medicine at the Children's Hospital of Philadelphia. Dr. Priore maintains a significant interest in investigating and developing RNA-based molecular diagnostic testing. In addition, he is actively involved in teaching and developing novel educational content in the areas of molecular pathology and medical humanities.

Dr. Priore is a diplomate of the American Board of Pathology.

(Continued on next page)

Anthony "Nino" Sireci, MD is the Vice President, Diagnostics Development at Loxo Oncology at Lilly. Dr. Sireci is a board-certified Clinical Pathologist and a practicing molecular pathologist. Prior to joining Loxo, he was an Assistant Professor of Pathology and Cell Biology at Columbia University and a medical director in the Laboratory of Personalized Genomic Medicine at Columbia Medical Center. He is an active member of the Association for Molecular Pathology (AMP) where he serves on the organizations' Strategy Committee and was the former vice chair for new codes and pricing on the Economic Affairs Committee. He is also a member of the Pathology Coding Caucus in the College of American Pathologists (CAP) and the Molecular Pathology Advisory Group in the American Medical Association (AMA). Dr. Sireci received a B.A in chemistry from New York University, an MD from the Johns Hopkins University School of Medicine and a Masters in Biostatistics from the Mailman School of Public Health at Columbia University. He completed his residency training in Clinical Pathology in the New York Presbyterian Hospital-Columbia, where he also served as chief resident.

About AMP

The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,500+ members include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees.

Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing.